Physician profile
James Kline
NPI 1811960347
$22,653.55
in general payments reported to CMS, 2019-2025
37 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,914 · 2022: $1,817 · 2023: $2,439 · 2024: $5,613 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,472 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,425 · Travel and Lodging: $1,777 · Consulting Fee: $1,080 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,471.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,425.00 |
| Travel and Lodging | $1,776.63 |
| Consulting Fee | $1,080.00 |
| Education | $170.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $10,853.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $3,507.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,200.55 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,022.95 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $877.07 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $573.73 | 2021-2024 | Zeposia |
| Pfizer INC. | $498.39 | 2021-2025 | |
| Genzyme Corporation | $489.66 | 2022-2025 | |
| Ardelyx, INC. | $484.72 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $465.19 | 2021-2025 | Livdelzi |
| Qol Medical, LLC | $358.97 | 2021-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $338.67 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $240.47 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $225.34 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $165.31 | 2024-2025 | Terlivaz |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $161.35 | 2021-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $143.40 | 2021-2023 | |
| Lilly USA, LLC | $140.30 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $134.74 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $125.84 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $93.45 | 2021-2022 | |
| Daiichi Sankyo INC. | $92.92 | 2021-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $79.65 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $63.00 | 2023 | |
| Merck Sharp & Dohme LLC | $56.57 | 2022-2024 | Dificid, Zerbaxa, Zinplava |
| Novo Nordisk INC | $38.21 | 2025 | Wegovy |
| Redhill Biopharma INC. | $37.73 | 2021 | |
| Braintree Laboratories, INC. | $27.47 | 2022 | |
| Grifols USA, LLC | $27.12 | 2024 | Xembify |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | |
| Organon LLC | $17.03 | 2025 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2024 | Cyltezo |
| Amgen INC. | $15.54 | 2025 | Uplizna |
| Orphalan INC | $15.12 | 2025 | Cuvrior |
| Teleflex LLC | $14.24 | 2024 | Solesta |
| Recordati_rare_diseases_inc. | $13.78 | 2025 | Panhematin |
| Evoke Pharma, INC. | $13.52 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.